

Key Contacts

My Patient Navigator

Name: _____

Phone: _____

My Clinical Education Manager (CEM)

Name: _____

Phone: _____

Specialty Pharmacy

Name: _____

Phone: _____

Genentech Co-pay Program

Phone: 844-672-6729

Genentech Patient Foundation

Phone: 888-941-3331

Infusion Center/Injection Provider

Name: _____

Phone: _____

Alternate Infusion Center/Injection Provider

Name: _____

Phone: _____

OCREVUS ZUNOVO™
ocrelizumab & hyaluronidase-ocsq
Subcutaneous injection 920mg/23,000 units



OCREVUS®
ocrelizumab IMMUNE RESPONSE



It's time to
get ready for
**YOUR FIRST
TREATMENT**

OCREVUS ZUNOVO™
ocrelizumab & hyaluronidase-ocsq
Subcutaneous injection 920mg/23,000 units



OCREVUS®
ocrelizumab IMMUNE RESPONSE



WANDA

Using
OCREVUS ZUNOVO®

For OCREVUS® [IV], your first dose will be split into 2,
for a total of 3 treatments your first year.

©2025 Genentech USA, Inc. All rights reserved. M-US-00015591(v7.0) 9/25

Before Your First Treatment: Next Steps

Once your doctor has prescribed OCREVUS® [IV] or OCREVUS ZUNOVO®, follow these steps to prepare for your first treatment. Be sure to hold on to this brochure for the future.



1



Complete forms & labs

If you wish to enroll in OCREVUS Access Solutions, sign the Patient Consent section in the OCREVUS Start Form available at ocrevus.com/forms. Your healthcare provider will fill out the prescriber section and, if needed, provide a treatment referral. Together with your healthcare provider: **1. Choose** your treatment site. **2. Make a plan** to complete your labs and vaccines.*

*Important Safety Information about vaccines and more can be found on the next page and in the Prescribing Information for OCREVUS and for OCREVUS ZUNOVO.

2



Review the Welcome Guide

Read through the Welcome Guide once you receive it. Write down any questions you may have for your doctor or your Patient Navigator.

If you didn't receive your Welcome Guide, download it at ocrevus.com/welcomeguide, or if you're working with a Patient Navigator, you can ask them to send you a copy.

3



Talk to your Patient Navigator

Once both OCREVUS Start Forms have been received, your OCREVUS Patient Navigator will call you in approximately 1 week to explain:

Patient support services, including finding a treatment provider (site of treatment) | Insurance coverage† | Financial and administrative needs (such as co-pay assistance) | Alternative funding resources

If you didn't receive a call, contact OCREVUS Access Solutions at 1-800-888-2882 to speak to a Patient Navigator.

4



Schedule & prepare for your treatment

Once you have insurance authorization, you will be able to schedule your treatment. Your healthcare provider can answer any questions regarding your authorization. Together with your healthcare provider, confirm all labs are complete and vaccinations have been received in the recommended time frame.

Download the OCREVUS Appointment Checklist at ocrevus.com/appointmentchecklist to make sure you're ready.

5



Your first treatment

If receiving OCREVUS ZUNOVO, your first injection with premedication and post-injection observation will last at least 1 hour and 40 minutes, depending on how your premedications are administered. There is no split first dose.

If receiving OCREVUS [IV], your first infusion will be split into 2 doses, 2 weeks apart. These two appointments with premedication and post-infusion observation will each last about 4 hours and 30 minutes. Appointments after that will last about 5 hours and 30 minutes to 6 hours.

Your Patient Navigator will call you approximately 2 weeks after your treatment to:

Answer any questions you may have | Ask if you've scheduled your next treatment | Talk about ongoing support and future check-ins

What is treatment with OCREVUS like?

Find out more and watch the OCREVUS administration videos.



Watch Now

†Please notify your Patient Navigator if there have been any changes with your insurance. Please see Important Safety Information about OCREVUS and OCREVUS ZUNOVO on the next page.

OCREVUS ZUNOVO™
ocrelizumab & hyaluronidase-ocsq
Subcutaneous injection 920mg/23,000 units



OCREVUS®
ocrelizumab
INTRAVENOUS INJECTION



Important Safety Information

What are OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults.

It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

Who should not receive OCREVUS or OCREVUS ZUNOVO?

Do not receive OCREVUS or OCREVUS ZUNOVO if you:

- have an active hepatitis B virus (HBV) infection.
- have had a life-threatening administration reaction to ocrelizumab.
- have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Infusion reactions (OCREVUS):** Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.
- **Injection reactions (OCREVUS ZUNOVO):** Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.

Tell your healthcare provider or nurse if you get any of these symptoms:

- | | |
|-----------------------------|-----------------------------------|
| • itchy skin | • redness on your face (flushing) |
| • rash | • nausea |
| • hives | • headache |
| • tiredness | • swelling of the throat |
| • coughing or wheezing | • dizziness |
| • trouble breathing | • shortness of breath |
| • throat irritation or pain | • fatigue |
| • feeling faint | • fast heartbeat |
| • fever | |

Additionally, for OCREVUS ZUNOVO:

- | | | |
|-----------------------|------------|-----------|
| • injection site pain | • swelling | • redness |
|-----------------------|------------|-----------|

These infusion and injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion or injection.

• Infection:

- Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract

infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS or OCREVUS ZUNOVO. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.

- **Hepatitis B virus (HBV) reactivation:** Before starting treatment with ocrelizumab, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS or OCREVUS ZUNOVO.

- **Weakened immune system:** OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

- **Progressive Multifocal Leukoencephalopathy (PML):** PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:

- | | |
|------------|-----------------------------------|
| • thinking | • balance |
| • eyesight | • weakness on 1 side of your body |
| • strength | • using your arms or legs |

- **Decreased immunoglobulins:** OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving OCREVUS or OCREVUS ZUNOVO, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection. See **“What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?”**
- have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. These medicines could increase your risk of getting an infection.
- have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have a history of inflammatory bowel disease or colitis.
- have a history of liver problems.
- have had a recent vaccination or are scheduled to receive any vaccinations.
- **You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with OCREVUS or OCREVUS ZUNOVO and until your healthcare provider tells you that your immune system is no longer weakened.**
- **When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.** If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS or OCREVUS ZUNOVO, talk to your healthcare provider.

- If you have a baby and you received OCREVUS or OCREVUS ZUNOVO during your pregnancy, it is important to tell your baby's healthcare provider about receiving OCREVUS or OCREVUS ZUNOVO so they can decide when your baby should be vaccinated.
- are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS and OCREVUS ZUNOVO will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and OCREVUS ZUNOVO and for 6 months after your last dose of OCREVUS or OCREVUS ZUNOVO. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving OCREVUS or OCREVUS ZUNOVO.
- are breastfeeding or plan to breastfeed. It is not known if OCREVUS and OCREVUS ZUNOVO pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS or OCREVUS ZUNOVO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO may cause serious side effects, including:

- **Risk of cancers (malignancies) including breast cancer:** Follow your healthcare provider's instructions about standard screening guidelines for breast cancer.
- **Inflammation of the colon, or colitis:** Tell your healthcare provider if you have any symptoms of colitis, such as:
 - Diarrhea (loose stools) or more frequent bowel movements than usual
 - Stools that are black, tarry, sticky or have blood or mucus
 - Severe stomach-area (abdomen) pain or tenderness
- **Liver damage.** OCREVUS and OCREVUS ZUNOVO may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start OCREVUS or OCREVUS ZUNOVO and while you take OCREVUS or OCREVUS ZUNOVO if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as:
 - yellowing of the skin and eyes (jaundice)
 - nausea
 - vomiting
 - unusual darkening of the urine
 - feeling tired or weak

The most common side effects of OCREVUS ZUNOVO include:

- Injection reactions
- Respiratory tract infections
- Skin infections

These are not all the possible side effects of OCREVUS and OCREVUS ZUNOVO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (888) 835-2555.

For more information, go to www.OCREVUS.com or call 1-844-627-3887.

Please see additional Important Safety Information throughout and click here for full [Prescribing Information](#) and [Medication Guide for OCREVUS](#).

Please see additional Important Safety Information throughout and click here for full [Prescribing Information](#) and [Medication Guide for OCREVUS ZUNOVO](#).

OCREVUS ZUNOVO™
ocrelizumab & hyaluronidase-ocsq
Subcutaneous injection 920mg/23,000 units



OCREVUS®
ocrelizumab
ORAL SOLUTION

